Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 28.90
-2.32 (-7.43%)
Sep 10, 2026, 11:59 AM HKT
Everest Medicines Market Cap
Everest Medicines has a market cap or net worth of 10.98 billion as of September 9, 2026. Its market cap has decreased by -49.96% in one year.
Market Cap
10.98B
Enterprise Value
10.92B
Revenue
2.78B
Ranking
n/a
PE Ratio
n/a
Stock Price
28.90
ChartMarket Cap Chart
Since October 9, 2020, Everest Medicines's market cap has decreased from 20.64B to 10.98B, a decrease of -46.82%. That is a compound annual growth rate of -10.12%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 9, 2026 | 10.98B | -15.98% |
| Dec 31, 2025 | 13.06B | -16.21% |
| Dec 31, 2024 | 15.59B | 132.87% |
| Dec 29, 2023 | 6.70B | 24.60% |
| Dec 30, 2022 | 5.37B | -47.96% |
| Dec 31, 2021 | 10.33B | -47.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ascentage Pharma Group International | 12.57B |
| HBM Holdings | 12.53B |
| Nanjing Leads Biolabs | 12.33B |
| Ascletis Pharma | 10.63B |
| Suzhou Ribo Life Science | 9.84B |
| CStone Pharmaceuticals | 9.83B |
| GenFleet Therapeutics (Shanghai) | 9.74B |
| Shaanxi Micot Pharmaceutical Technology | 8.64B |